Keros Therapeutics (KROS) Total Non-Current Liabilities (2019 - 2021)

Keros Therapeutics' Total Non-Current Liabilities history runs 3 years deep, the most recent figure standing at $12.1 million for Q4 2021.

• Quarterly Total Non-Current Liabilities rose 57.66% year-over-year to $12.1 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $12.1 million (up 57.66% YoY) and the FY2021 annual result came in at $12.1 million, up 57.66% from the prior year.
• Total Non-Current Liabilities was $12.1 million for Q4 2021 at Keros Therapeutics, up from $11.5 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $12.1 million in Q4 2021 and bottomed at $7.4 million in Q3 2020.
• A 3-year average of $9.4 million and a median of $9.3 million in 2021 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2020 — Total Non-Current Liabilities decreased 25.93% — and 2021, when it surged 57.66%.
• Keros Therapeutics' Total Non-Current Liabilities stood at $10.3 million in 2019, then retreated by 25.93% to $7.7 million in 2020, then jumped by 57.66% to $12.1 million in 2021.
• Business Quant data shows KROS's Total Non-Current Liabilities at $12.1 million in Q4 2021, $11.5 million in Q3 2021, and $7.8 million in Q2 2021.